Government likely to be forced to rethink its strategy for Polfa

After numerous changes to the government's consolidation program, it is currently supposed to encompass three companies: Polfa Warszawa, Polfa Pabianice and loss-making Polfa Tarchomin, with the merged concern to be floated on the stock exchange at the end of this year. However, government plans for the company do not sound enticing to potential investors. Its main role is supposed to be a "social" one, providing the public with inexpensive medicines. At the same time it is supposed to compete on EU markets and invest in developing new medicines. "No investor will invest in such a dubious company, particularly one supervised by bureaucrats," said Andrzej Sadowski from the Adam Smith Center. (Puls Biznesu, p. 4) T.J.